Evolutionary medicine: A meaningful connection between omics, disease, and treatment.
The evolutionary nature of diseases requires that their omics be analyzed by evolution-compatible analytical tools such as parsimony phylogenetics in order to reveal common mutations and pathways' modifications. Since the heterogeneity of the omics data renders some analytical tools such as phenetic clustering and Bayesian likelihood inefficient, a parsimony phylogenetic paradigm seems to connect between the omics and medicine. It offers a seamless, dynamic, predictive, and multidimensional analytical approach that reveals biological classes, and disease ontogenies; its analysis can be translated into practice for early detection, diagnosis, biomarker identification, prognosis, and assessment of treatment. Parsimony phylogenetics identifies classes of specimens, the clades, by their shared derived expressions, the synapomorphies, which are also the potential biomarkers for the classes that they delimit. Synapomorphies are determined through polarity assessment (ancestral vs. derived) of m/z or gene-expression values and parsimony analysis; this process also permits intra and interplatform comparability and produces higher concordance between platforms. Furthermore, major trends in the data are also interpreted from the graphical representation of the data as a tree diagram termed cladogram; it depicts directionality of change, identifies the transitional patterns from healthy to diseased, and can be developed into a predictive tool for early detection.
Abu-Asab
Mones
M
Laboratory of Pathology, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.
Chaouchi
Mohamed
M
Amri
Hakima
H